In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Post hoc analysis provides new insights on sacubitril/valsartan in myocardial infarction

PARADISE-MI trial presented in a Hot Line Session today at ESC Congress 2022

Cardiovascular Pharmacotherapy

Barcelona, Spain – 29 Aug 2022: Sacubitril/valsartan is superior to ramipril in high-risk survivors of acute myocardial infarction, according to a post hoc win ratio analysis of the PARADISE-MI trial presented in a Hot Line session today at ESC Congress 2022.1

Study author Dr. Otavio Berwanger of the Academic Research Organization (ARO), Hospital Israelita Albert Einstein, Sao Paulo, Brazil said: “The win ratio was introduced in 2012 as a novel approach for examining composite endpoints in clinical trials. The win ratio accounts for both the clinical relevance and timing of individual components of an endpoint – more serious events are given a higher priority and are analysed first – making it a useful method for analysing composite outcomes in cardiovascular trials. Applying this method to the PARADISE-MI trial extends our understanding of the effects of sacubitril/valsartan in patients with acute myocardial infarction.”

The primary results of the PARADISE-MI trial were previously reported.2 The trial randomly assigned 5,661 patients with acute myocardial infarction complicated by a reduced left ventricular ejection fraction (<40%), pulmonary congestion, or both to receive either the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan (97 mg of sacubitril and 103 mg of valsartan twice daily) or the angiotensin-converting enzyme (ACE) inhibitor ramipril (5 mg twice daily) on top of guideline-recommended therapy.3 The average age was 64 years and 24% were women. At a median follow up of 22 months, sacubitril/valsartan did not significantly reduce the primary composite outcome of death from cardiovascular causes or incident heart failure. Incident heart failure included hospitalisation for heart failure and outpatient episodes of symptomatic heart failure treated with intravenous or sustained oral diuretic therapy.

A post hoc win ratio analysis of the PARADISE-MI trial is presented today. The principal composite outcome was analysed in the hierarchical order of death due to cardiovascular causes, first hospitalisation for heart failure, and first outpatient episode of symptomatic heart failure. The researchers included events confirmed by the clinical event classification committee and events identified by investigators that did not meet study definitions (and were not included in the previously reported primary analysis), with adjudicated events given a higher priority and computed first (see figure). Results were analysed by the unmatched win ratio method, where every patient in the sacubitril/valsartan group is compared with every patient in the ramipril group. The win ratio is the total number of winner pairs divided by the total number of loser pairs. A win ratio that exceeds 1.00 favours sacubitril/valsartan. The analyses included all randomised participants according to the intention-to-treat principle.

In this analysis, sacubitril/valsartan was superior to ramipril. The hierarchical analysis of the principal composite outcome of cardiovascular death, hospitalisation for heart failure, and outpatient heart failure demonstrated a larger number of wins (1,265,767 [15.7%]) than losses (1,079,502 [13.4%]) in the sacubitril/valsartan group, for a win ratio of 1.17 (95% confidence interval 1.03–1.33; p=0.015). The two main contributors to the number of wins were death due to cardiovascular causes (36.9% of wins) and hospitalisation for heart failure (29.8% of wins).

Dr. Berwanger said: “The results suggest that if any two patients are compared, one on sacubitril/valsartan and one on ramipril, and they are not a tie, then there is a 1.17 odds that the sacubitril/valsartan patient is the winner. These exploratory analyses do not alter the primary neutral results for the drug in acute myocardial infarction, but they do provide supportive evidence to guide decisions to replace ACE inhibitors with sacubitril/valsartan once symptomatic heart failure has developed. The study illustrates how the win ratio approach may be a useful adjunct to the conventional time-to-first event analysis for trials with composite outcomes, especially where ranking the clinical importance of the different types of events is considered relevant.”


Figure: Win ratio analysis of the PARADISE-MI trial

Diagram, timelineDescription automatically generated



Notes to editor

ESC Press Office
Tel: +33 (0) 7 8531 2036

Follow us on Twitter @ESCardioNews 

The hashtag for ESC Congress 2022 is #ESCCongress.


This press release accompanies both a presentation and an ESC press conference at ESC Congress 2022. It does not necessarily reflect the opinion of the European Society of Cardiology.


Funding: The executive committee designed and oversaw the conduct of the trial and data analysis, in collaboration with the sponsor, Novartis.


Disclosures: Otavio Berwanger reports research grants from AstraZeneca, Bayer, Amgen, Novartis, Servier, BMS, and Pfizer paid to his institution.


References and notes

1PARADISE-MI will be discussed during Hot Line Session 8 on Monday 29 August at 08:30 to 10:00 CEST in the Barcelona auditorium.

2Pfeffer MA, Claggett B, Lewis EF, et al. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. N Engl J Med. 2021;385:1845–1855.

3Jering KS, Claggett B, Pfeffer MA, et al. Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. 2021;23:1040–1048.


About the European Society of Cardiology

The ESC brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.

About ESC Congress 2022

It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Barcelona and online – from 26 to 29 August. Explore the scientific programme. More information is available from the ESC Press Office at